Importantly, this protective effect was independent of changes in body weight, suggesting that CD36 peptide, acting as an antagonist for TSP1, may offer a new therapeutic option for managing obesity-associated metabolic dysfunction. This evidence concerns the gene CD36 and obesity due to melanocortin 4 receptor deficiency.